Celldex Therapeutics, Inc. Restricted Cash and Cash Equivalents, Noncurrent
Celldex Therapeutics, Inc. (CLDX) had Restricted Cash and Cash Equivalents, Noncurrent of $200.00 thousand as of 2012-12-31, per its 10-K filed 2013-03-08.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2013-03-08
- 2012-12-31: Restricted Cash and Cash Equivalents, Noncurrent $200.00K.
- 2011-12-31: Restricted Cash and Cash Equivalents, Noncurrent $200.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2012-12-31 | $200.00K 10-K · filed 2013-03-08 |
| 2011-12-31 | $200.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |